The OBIO® 2025 Early Technology Showcase (ETS) will feature presentations from Canada’s leading research institutions and healthcare organizations to global investors. ETS partners are invited to present the most promising technologies as well as introduce projects with the greatest potential for commercialization in their research portfolios and emerging health science companies.
Presenting organizations
More partners & their spin-outs to be announced soon.
Conscience is a non-profit organization driving innovation in drug development where traditional markets fall short. Through our network of researchers, industry leaders, and SMEs, we build open collaborations that reduce inefficiencies and drive progress in drug discovery. Our CACHE (Critical Assessment of Computation Hit-finding Experiments) Challenges offer participants a chance to have their computational drug discovery methods tested through experimental validation by leading labs. Post-challenge, all data is shared openly, providing participants with performance metrics to attract investors and advance the field. Our Developing Medicines through Open Science (DMOS) program funds preclinical drug development in neglected areas, fostering collaborations that establish proof of concept for an open science path to drug development, support Canadian SMEs, and generate economic activity - all while working toward affordable and accessible medicines for all.
Binary Star Research Services is focusing on G-protein coupled receptors, combines classical all-atomic calculations, extensive expertise in protein and nucleic acid modelling, and AI and machine learning methods to help partners discover innovative hit molecules from our 25 billion compound library and conduct minimal-cost lead development.
Molecular Forecaster Inc. combines proprietary software and multidisciplinary domain expertise to deliver customized, collaborative computer-aided drug discovery (CADD) solutions and strategic value in small molecule design.
McMaster University is a leader in health sciences research, and is recognized internationally in biomedical innovation. McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery.
BiCova is developing Covalent Bifunctional small Molecules that can bridge multiple protein targets to trigger and sustain proximity induction processes such as immune cell activation and protein degradation.
Organobiotech is the first to integrate 3D printing of sacrificial materials into multi-well plates, enabling the development of high-throughput tissue culture platforms that empower end-users to create more effective preclinical models.
The Hospital for Sick Children (SickKids) is Canada’s leading research-intensive hospital and the nation’s largest centre dedicated to advancing children’s health. Every day, we strive to deliver exceptional child and family-centred care, achieve groundbreaking clinical and scientific advancements, and train the next generation of pediatric health experts. With over 3,000 scientists, researchers, and technicians, SickKids drives transformative discoveries that shape the future of health care. The Industry Partnerships and Commercialization (IP&C) Office at SickKids plays a pivotal role in translating these discoveries into real-world impact by identifying, developing, and commercializing cutting-edge health innovations. Through collaborations with entrepreneurs, industry leaders, and investors, IP&C delivers revolutionary healthcare solutions to patients worldwide.
iMünRx is focusing on developing the platform for areas of high unmet need in lung health like Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, and lung cancer where current therapies targeting single pathways have demonstrated limited ability to halt disease progression. iMünRx has developed a macrophage-based iPSC-derived cell therapy platform to treat lung diseases we call Alveolar-like Macrophages (ALMs). ALMs are engineered to be a fit for purpose product leveraging the body’s own systems to address all drivers of lung disease in a single therapeutic product.
IonCan is developing an ion channel complex-targeting designer peptide to kill GBM cells without affecting normal cells. A first in class therapeutic agent to treat glioblastoma via a novel unprecedented mechanism of action. Our studies in mice show unprecedented efficacy in reducing GBM tumour burden with no toxicity. The designer peptide targets GBM cells that are resistant to the frontline chemotherapy temozolomide. The company is seeking seed funding to complete pre-clinical validation studies and file an IND.
The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 7,000 highly qualified personnel have been trained. In 2023, the Government of Canada announced additional funding for SCN through the Strategic Science Fund that will support SCN activities and research through to the end of the decade.
Tessella Biosciences is producing the most advanced bioinks that propel the future of bioprinting, advanced tissue models and regenerative medicine.
University Health Network (UHN) is Canada's No. 1 hospital and the world's No. 1 publicly funded hospital, with 10 sites and more than 20,000 staff members. UHN consists of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education at UHN and West Park Healthcare Centre. As Canada's top research hospital, the scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. UHN’s strengths include advancements in regenerative medicine, cell therapies, immunology, transplant and oncology.
Medly encourages patients to take control of their chronic conditions by providing self-care guidance and access to their care team from home.
NovaKonexus™ is pioneering transformative innovations in rehabilitation and healthcare, leveraging advanced technologies to address critical needs in neurorehabilitation, orthopaedics, and geriatrics. Our solutions integrate artificial intelligence, robotics, wearable sensors, and digital health platforms, ensuring personalized, scalable, and effective care for patients worldwide.